Bristol-Myers Squibb vs Thermo Fisher Scientific stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Bristol-Myers Squibb is cheaper for its profits and has less debt. Thermo Fisher Scientific is more profitable and grows faster.
Side by side
| Bristol-Myers Squibb | Thermo Fisher Scientific | |
|---|---|---|
| $130 billion | $259 billion | |
| 14.6% | 15.0% | |
| +2.5% | +6.7% | |
| 18.4× | 38.7× | |
| 2.4 years | 2.6 years | |
| 13.9% | 7.6% | |
| 4.4% | 0.4% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Bristol-Myers Squibb vs UnitedHealth · Bristol-Myers Squibb vs AbbVie · Bristol-Myers Squibb vs Amgen · Bristol-Myers Squibb vs Intuitive Surgical · Thermo Fisher Scientific vs Intuitive Surgical · Thermo Fisher Scientific vs Johnson & Johnson · Thermo Fisher Scientific vs Eli Lilly · Thermo Fisher Scientific vs Medtronic

